On September 8, 2020 Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ("Aptorum Group" or "Aptorum"), a biopharmaceutical company focused on novel therapeutics including the development of next-generation approach therapeutics targeting antimicrobial resistance, reported President and Executive Director, Mr. Darren Lui, will share insight into the company’s recent developments and upcoming milestones at an investor webinar and the Wall Street Investor Forum on Thursday, September 10, 2020 (Press release, Aptorum, SEP 8, 2020, View Source [SID1234564764]). The details are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investor Webinar and Q&A session

Date: Thursday, September 10, 2020
Time: 4:00 PM Eastern Time

To participate in the webinar, please register at:
View Source

Questions can be pre-submitted to [email protected] or online during the event.

The Wall Street Investor Forum

Date: Thursday, September 10, 2020
Time: 1:00 PM Eastern Time

To listen to Aptorum Group’s presentation, please register at
View Source